A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without
epidermal growth factor receptor
mutations and
anaplastic lymphoma kinase
rearrangement
2020 ◽
Vol 16
(4)
◽
pp. 850
2003 ◽
Vol 13
(5)
◽
pp. 289-298
◽
2015 ◽
Vol 19
(6)
◽
pp. 734-742
◽
2014 ◽
Vol 37
(4)
◽
pp. 343-349
◽